# Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

> **NCT02212886** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mapi Pharma Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** GA Depot 80 mg
- **DRUG:** GA Depot 40 mg

## Key facts

- **NCT ID:** NCT02212886
- **Lead sponsor:** Mapi Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2017-05
- **Final completion:** 2024-11-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02212886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02212886, "Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02212886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*